Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are no effective treatments or validated clinical response markers in systemic sclerosis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a single-arm open-label clinical trial of tyrosine kinase inhibitor dasatinib in patients with SSc-associated interstitial lung disease (SSc-ILD). METHODS: Primary objectives were safety and pharmacokinetics. Secondary outcomes included clinical assessments, quantitative high-resolution computed tomography (HRCT) of the chest, serum biomarker assays and skin biopsy-based gene expression subset assignments. Clinical response was defined as decrease of >5 or >20% from baseline in the modified Rodnan Skin Score (MRSS). Pulmonary function was assessed at baseline and day 169. RESULTS: Dasatinib was well-tolerated in 31 patients receiving drug for a median of nine months. No significant changes in clinical assessments or serum biomarkers were seen at six months. By quantitative HRCT, 65% of patients showed no progression of lung fibrosis, and 39% showed no progression of total ILD. Among 12 subjects with available baseline and post-treatment skin biopsies, three were improvers and nine were non-improvers. Improvers mapped to the fibroproliferative or normal-like subsets, while seven out of nine non-improvers were in the inflammatory subset (p = 0.0455). Improvers showed stability in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), while both measures showed a decline in non-improvers (p = 0.1289 and p = 0.0195, respectively). Inflammatory gene expression subset was associated with higher baseline HRCT score (p = 0.0556). Non-improvers showed significant increase in lung fibrosis (p = 0.0313). CONCLUSIONS: In patients with SSc-ILD dasatinib treatment was associated with acceptable safety profile but no significant clinical efficacy. Patients in the inflammatory gene expression subset showed increase in skin fibrosis, decreasing pulmonary function and worsening lung fibrosis during the study. These findings suggest that target tissue-specific gene expression analyses can help match patients and therapeutic interventions in heterogeneous diseases such as SSc, and quantitative HRCT is useful for assessing clinical outcomes. TRIAL REGISTRATION: Clinicaltrials.gov NCT00764309.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig 6 HRCT trends across improvers and non-improvers. (A) QGG trends. (B) QLF trends. (C) Baseline [QGG-QLF] marker vs. intrinsic subset. (D) Baseline [QGG-QLF] marker vs. response status.](https://figures.cochat.ai/paper-figures/b69ea3636a8a47a3ad90607025967612/novel-lung-imaging-biomarkers-and-skin-gene-expression-subsetting-in-dasatinib-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety and tolerability with DQ are substantiated by acceptable safety profile of 9 months of daily D use in participants with systemic sclerosis with associated interstitial lung disease (SSc-ILD): mild-moderate severity diarrhea and nausea were most common reported adverse events [53].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 2×
“Briefly, differentially PLOS ONE | https://doi.org/10.1371/journal.pone.0187580 November 9, 2017 4 / 20 expressed genes were determined using GenePattern [37] module ComparativeMarkerSelection [38] and differentially expressed pathways were identified via Gene Set Enrichment Analysis [39,40] run vs. Hallmark database…”
MethodInfluentialThe Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197 · cited 2×
“Briefly, differentially PLOS ONE | https://doi.org/10.1371/journal.pone.0187580 November 9, 2017 4 / 20 expressed genes were determined using GenePattern [37] module ComparativeMarkerSelection [38] and differentially expressed pathways were identified via Gene Set Enrichment Analysis [39,40] run vs. Hallmark database…”
MethodInfluentialPreliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 2×
“Image data were processed using Robust Multichip Average (RMA) [34] to determine specific hybridizing signal for each gene.”
MethodScleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,032
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Changes in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528 · cited 1×
“Progressive fibrosis in the skin and lungs accounts for the significant morbidity and mortality of SSc [3].”
BackgroundInterstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230 · cited 1×
“The extent of radiologic lung involvement at baseline is a strong predictor of both subsequent disease progression and mortality in patients with SSc [52].”
Background
Cited by
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261
“Safety and tolerability with DQ are substantiated by acceptable safety profile of 9 months of daily D use in participants with systemic sclerosis with associated interstitial lung disease (SSc-ILD): mildmoderate severity diarrhea and nausea were most common reported adverse events [53].”
BackgroundShared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Self-citationCurrent Concepts on the Pathogenesis of Systemic Sclerosis
Truchetet, M. E., Brembilla, N. C., & Chizzolini, C. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08889-8 · Cited by 170
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
The costs and benefits of senotherapeutics for human health
Raffaele, M., & Vinciguerra, M. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00300-7 · Cited by 140
Emerging targets of disease-modifying therapy for systemic sclerosis
Volkmann, E. R., & Varga, J. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0184-z · Cited by 145
Self-citationKulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 140
“…with CKD (Hickson et al., 2019) • In pts with ILD, by HRCT, 65% showed no progression in lung fibrosis and 39% showed no progression in total ILD, > historical controls; 23/31 participants analyzed (Martyanov et al., 2017) No applicable studies No applicable studies Aspirin No applicable studies.”
BackgroundChallenges in developing Geroscience trials
Rolland, Y., Sierra, F., Ferrucci, L., Barzilai, N., De Cabo, R., Mannick, J., Oliva, A., Evans, W., Angioni, D., De Souto Barreto, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39786-7 · Cited by 91
Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review
Zhao, M. F., Wu, J., Wu, H., Sawalha, A. H., & Lu, Q. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08831-4 · Cited by 97
“The efficacy of dasatinib, another second-generation TKI, was evaluated in SSc-ILD patients, demonstrating that the agent was well tolerated but without significant clinical efficacy [63].”
BackgroundMajor lung complications of systemic sclerosis
Denton, C. P., Wells, A. U., & Coghlan, G. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0062-0 · Cited by 91
Ko, J., Noviani, M., Chellamuthu, V. R., Albani, S., & Low, A. H. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814287 · Cited by 85
“In contrast, patients with fibro-proliferative gene signatures, but not the inflammatory gene signatures, were found to respond to tyrosine kinase inhibitor nilotinib, imatinib, and dasatinib [137–139].”
BackgroundThe promise of precision medicine in rheumatology
Guthridge, J. M., Wagner, C. A., & James, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01880-6 · Cited by 92
Vacchi, C., Sebastiani, M., Cassone, G., Cerri, S., Casa, G. D., Salvarani, C., & Manfredi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020407 · Cited by 74
“[24] 2017 31 SSc-ILD Phase IIa 18 Mo * Dasatinib Dasatinib for 6 months II: PFT, PR-D, HRCT, Serum KL-6, SP-D, APRIL and adiponectin.”
BackgroundCellular Senescence in Idiopathic Pulmonary Fibrosis
Kellogg, D. L., Kellogg, D. L., Musi, N., & Nambiar, A. M. (2021) · Current Molecular Biology Reports · doi:10.1007/s40610-021-00145-4 · Cited by 67
Senescence and tissue fibrosis: opportunities for therapeutic targeting
O’Reilly, S., Tsou, P., & Varga, J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.012 · Cited by 72
Self-citationDańczak‐Pazdrowska, A., Gornowicz‐Porowska, J., Polańska, A., Krajka‐Kuźniak, V., Stawny, M., Gostyńska, A., Rubiś, B., Noureddine, S. A., Ashiqueali, S., Schneider, A., et al. (2023) · Aging Cell · doi:10.1111/acel.13845 · Cited by 71
Cellular Senescence and Senotherapies in the Kidney: Current Evidence and Future Directions
Docherty, M. H., Baird, D., Hughes, J., & Ferenbach, D. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00755 · Cited by 69
A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model
Seger, S., Stritt, M., Vezzali, E., Nayler, O., Hess, P., Groenen, P. M. A., & Stalder, A. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193057 · Cited by 66
Checa, J., & Aran, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239317 · Cited by 61
Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention
Fischer, A., Patel, N. M., & Volkmann, E. R. (2019) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s226695 · Cited by 61
“In a single-arm, open-label, phase IIa study of dasatinib in SSc-ILD (NCT00764309), the safety profile was acceptable.(131) No significant changes at Day 169 versus baseline were observed in mRSS or PFTs, but comparison with a historical, placebo-treated control group indicated that dasatinib may have reduced the rate…”
BackgroundMartyanov, V., Whitfield, M. L., & Varga, J. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40934 · Cited by 52
“To address the potential pathogenic role of cellular senescence in SSc- associated ILD (SScILD), we reexamined our results from a recent single- arm clinical trial of dasatinib (2), in which 12 patients with SSc- ILD received treatment for 169 days.”
ResultSelf-citationPDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis
Paolini, C., Agarbati, S., Benfaremo, D., Mozzicafreddo, M., Svegliati, S., & Moroncini, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073904 · Cited by 55
“Dasatinib has been evaluated in a small cohort of patients with diffuse SSc in an open-label uncontrolled study, failing to show any significant improvement in skin and lung outcomes [73].”
BackgroundInsulin-like growth factor (IGF)-II- mediated fibrosis in pathogenic lung conditions
Garrett, S. M., Hsu, E., Thomas, J. M., Pilewski, J. M., & Feghali‐Bostwick, C. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225422 · Cited by 49
Aging, senescence, and cutaneous wound healing—a complex relationship
O’Reilly, S., Markiewicz, E., & Idowu, O. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429716 · Cited by 48
Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma
Bueno, M., Papazoglou, A., Valenzi, E., Rojas, M. M., Lafyatis, R., & Mora, A. L. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00920-9 · Cited by 40
Zaafan, M. A., & Abdelhamid, A. M. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1995379 · Cited by 40
Clark, K. E. N., Campochiaro, C., Csomor, E., Taylor, A. R., Nevin, K., Galwey, N. W., Morse, M. A., Singh, J., Teo, Y. V., Ong, V. H., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220402 · Cited by 35
“Some recent studies have analysed intrinsic subset gene sets, which found patients who responded to MMF or abatacept (a CTLA4-Ig fusion protein) tended to be in the inflammatory subset [11, 23] whereas those who responded to dasatinib (a tyrosine kinase inhibitor with anti-fibrotic potential) were in the fibroprolifer…”
BackgroundShowalter, K., Spiera, R., MAGRO, C. M. J., Agius, P., Martyanov, V., Franks, J. M., Sharma, R., Geiger, H. M., Wood, T. A., Zhang, Y., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217840 · Cited by 33
Self-citationPharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence
Vonk, M. C., Smith, V. M., Sfikakis, P. P., Cutolo, M., Galdo, F. D., & Seibold, J. R. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102978 · Cited by 36
“In patients treated with dasatinib, 23/31 patients had matched baseline and 6-month follow-up HRCT scans [83].”
BackgroundInfluentialEmerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis
Abraham, D., Lescoat, A., & Stratton, R. J. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101252 · Cited by 30
“In a small open-label trial in SSc patients, dasatanib responsive individuals had higher senescence gene expression profile pre-treatment, compared to non-responders and decreasing SASP signature was associate with responsive skin sore and stable lung involvement (Martyanov et al., 2017).”
BackgroundResultInfluentialHoffmann‐Vold, A., Maher, T. M., Philpot, E. E., Ashrafzadeh, A., & Distler, O. (2021) · ERJ Open Research · doi:10.1183/23120541.00235-2020 · Cited by 31
Mendoza, F. A., Piera-Velázquez, S., & Jiménez, S. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.01.001 · Cited by 29
Recent advances steer the future of systemic sclerosis toward precision medicine
Lepri, G., Hughes, M., Bruni, C., Matucci‐Cerinic, M., & Bellando-Randone, S. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04834-5 · Cited by 27
Dixon, G., Thould, H., Wells, M., Tsaneva-Atanasova, K. T., Scotton, C. J., Gibbons, M., Barratt, S. L., & Rodrigues, J. C. L. (2025) · European Respiratory Review · doi:10.1183/16000617.0194-2024 · Cited by 32
Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies
Asano, Y., & Varga, J. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.12.007 · Cited by 24
Self-citationKIT as a therapeutic target for non-oncological diseases
Martínez‐Antón, A., Gras, D., BOURDIN, A. A., Dubreuil, P. C., & Chanez, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.008 · Cited by 24
Dasatinib Attenuates Fibrosis in Keloids by Decreasing Senescent Cell Burden
Darmawan, C. C., Hur, K., Kusumaningrum, N., Chung, J. H., Lee, S., & Mun, J. (2023) · Acta Dermato Venereologica · doi:10.2340/actadv.v103.4475 · Cited by 22
“In patients with systemic sclerosis-associated interstitial lung disease, dasatinib showed clinical improvement, with decreased expression of SASP and other senescence-related genes, thereby suggesting that cellular senescence is an important pathological component of fibrotic diseases (7, 11).”
Self-citationConnective Tissue Disease–Associated Interstitial Lung Disease
Antin-Ozerkis, D. E., & Hinchcliff, M. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.05.008 · Cited by 23
Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?
Cazzola, M., Matera, M. G., Rogliani, P., & Calzetta, L. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1492548 · Cited by 20
“In the meantime, a small single-arm open-label clinical trial of dasatinib in patients with systemic sclerosis–associated interstitial lung disease documented that this treatment was associated with acceptable safety profile but no significant clinical efficacy [63].”
BackgroundRepurposing digoxin for geroprotection in patients with frailty and multimorbidity
Lee, H., Wilson, D. V., Bunting, K. V., Kotecha, D., & Jackson, T. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101860 · Cited by 20
“, 2014), and only a small number of serious adverse events were reported (oedema, dyspnoea and pulmonary fibrosis)(Justice et al., 2019; Martyanov et al., 2017).”
BackgroundInfluentialAn interim report of the Scleroderma Clinical Trials Consortium working groups
Baron, M. G., Kahaleh, B., Bernstein, E. J., Chung, L. S., Clements, P. J., Denton, C. P., Domsic, R. T., Ferdowsi, N., Foeldvari, I., Frech, T., et al. (2018) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198318783926 · Cited by 19
Immunotherapy of systemic sclerosis
Katsiari, C. G., Simopoulou, T., Alexiou, I., & Sakkas, L. I. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1491508 · Cited by 23
Chiu, Y., Spierings, J., van Laar, J. M., Vries-Bouwstra, J. K. D., van Dijk, M. R., & Goldschmeding, R. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/i49d3o · Cited by 21
“Disease complications, n (%) ILD 2 (11) 1 (8) 1 (20) PAH 3 (17) 2 (15) 1 (20) Digital ulcers 3 (17) 2 (15) 1 (20)”
BackgroundInfluentialKeret, S., Rimar, D., Lansiaux, P., Feldman, E., Lescoat, A., Milman, N., & Farge, D. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103314 · Cited by 17
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets
Nevskaya, T., Pope, J. E., Turk, M., Shu, J., Marquardt, A., van den Hoogen, F. H. J., Khanna, D., Fransen, J., Matucci‐Cerinic, M., Baron, M. G., et al. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.201594 · Cited by 15
“Another study supported sub-division of lcSSc into two serological subtypes (Th/To positive and ACA-positive) with different internal organ involvement and outcome[49].”
BackgroundResultLettieri, S., Bertuccio, F. R., Frate, L. D., Perrotta, F., Corsico, A. G., & Stella, G. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010547 · Cited by 17
“In 31 patients with systemic sclerosis-associated ILD, dasatinib alone (100 mg daily for 6 months) was not effective [196].”
BackgroundCao, C., Zhao, W., Guo, J., Wang, Z., Lü, A., & Liang, C. C. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100154 · Cited by 14
Molecular “omic” signatures in systemic sclerosis
Mehta, B. K., Espinoza, M. E., Hinchcliff, M., & Whitfield, M. L. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2020.19192 · Cited by 15
“For instance, patients with SSc classified in the inflammatory intrinsic subset are more likely to respond to mycophenolate mofetil (8) and abatacept (19), whereas patients belonging to the fibroproliferative intrinsic subset may be more likely to benefit from imatinib mesylate (35) or dasatinib (36).”
BackgroundSelf-citationDrugs in phase I and phase II clinical trials for systemic sclerosis
Chung, M. P., & Chung, L. S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1743973 · Cited by 14
“In an open-label clinical trial of dasatinib, SSc patients with early-stage ILD (n = 31) tolerated the drug well, but there were no significant changes in mRSS or pulmonary function tests [79].”
BackgroundNAD + , Senolytics, or Pyruvate for Healthy Aging?
Zhou, F. (2021) · Nutrition and Metabolic Insights · doi:10.1177/11786388211053407 · Cited by 15
Kim, G. H. J., Shi, Y., Yu, W., & Wong, W. K. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106333 · Cited by 12
Self-citationTherapeutic molecular targets of SSc-ILD
Zhang, Y., & Distler, J. H. W. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319899013 · Cited by 13
Toward Molecular Stratification and Precision Medicine in Systemic Sclerosis
Noviani, M., Chellamuthu, V. R., Albani, S., & Low, A. H. L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.911977 · Cited by 10
“In a more recent trial analyzing response to dasatinib, improvers (n= 3, out of total of 12 subjects) mapped to the fibroproliferative or normal-like subsets, whereas most of the non-improvers (n = 7, out of 9 non-improvers) were in the inflammatory subsets (41).”
BackgroundRecurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib
Bergman, J. C., Ly, T. Y., Keating, M.-M., & Hull, P. R. (2018) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475418775663 · Cited by 8
Recent Advances in Localized Scleroderma
Takahashi, T., Takahashi, T., & Asano, Y. (2025) · Sclerosis · doi:10.3390/sclerosis3040040 · Cited by 7
Antifibrotics in systemic sclerosis
Martín-López, M., & Carreira, P. E. (2021) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2021.101671 · Cited by 7
Mast cell activation in the systemic sclerosis esophagus
Tom, K., Mehta, B. K., Hoffmann, A., Aren, K., Carns, M. A., Lee, J. J., Martyanov, V., Popovich, D., Kosarek, N. N., Wood, T. A., et al. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320941322 · Cited by 5
Self-citationFallet, B., & Walker, U. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1832466 · Cited by 5
Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis
Arai, K., Yoshifuji, K., Motomura, Y., Sonokawa, S., Suzuki, S., & Kumagai, T. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02618-w · Cited by 5
Tian, J., Ha, Y., Lee, J. S., Lee, E. Y., Goldin, J. G., & Kim, G. H. J. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70320 · Cited by 4
Self-citationSex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study
Rodriguez‐Martin, I., Kerick, M., Rangel‐Peláez, C., Rosa-Baez, C., Borrego‐Yaniz, G., Ortiz‐Fernández, L., del Castillo, A. G., Simeón‐Aznar, C. P., Callejas, J. L., Distler, O., et al. (2026) · The Lancet Rheumatology · doi:10.1016/s2665-9913(25)00376-5 · Cited by 2
Hughes, M., McMahan, Z. H., Assassi, S., Denton, C. P., & Providencia, R. A. (2026) · Rheumatology · doi:10.1093/rheumatology/keag084 · Cited by 1
“…those treated with unopposed oestrogen, compared with combined oestrogen and progesterone [30]. o f p a t i e n t s s h o w e d n o p r o - g r e ss i o n o f l u n g fi b r o s i s , a n d 39 % s h o w e d n o p r o - g r e ss i o n o f t o t a l I L D [ 47 ] N o c o n t r o ll e d s t u d i e s”
Prospects for Stratified and Precision Medicine in Systemic Sclerosis Treatment
Clark, K. E. N., & Derrett‐Smith, E. C. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00124-y · Cited by 1
What comes before scleroderma?
Bellando-Randone, S., Suliman, Y. A., Anwar, S., & Furst, D. E. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1003994 · Cited by 1
Cellular and Molecular Mechanisms of Fibrosis in Systemic Sclerosis
Trojanowska, M., Varga, J., & Lagares, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_18 · Cited by 2
Self-citationInterstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis
Chung, A., English, J., & Volkmann, E. R. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00121-1
Understanding and Therapeutically Targeting the Scleroderma Myofibroblast
Ocon, A. J., Lokineni, S., & Korman, B. D. (2022) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-021-00189-8
Autoimmunity in interstitial lung disease
Sambataro, G., Sambataro, D., Adiletta, V., & Leone, P. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85415-3.00006-4
Schumacher, B. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734825206.793563347
Systemic Sclerosis - Recent Advances and New Perspectives
Lakota, K., Pirkmajer, K. P., & Burja, B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.102205
Lv, X., Tang, W., Ou, S., Yang, F., Wang, W., Duan, X., & Wei, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4307133/v1
Old Techniques Still Have Relevance in Personalized Predictive Medicine
Clark, K. E. N., & Denton, C. P. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43402
“Early-phase clinical trials have suggested that, for example, fi broproliferative groups were more likely to respond to dasatinib, 8 whereas the in fl ammatory subset showed greater response to MMF compared to the fi broprolifera-tive group.”
Shi, Q., Zhang, J., Yu, Q., Gu, Y., Liu, J., Wang, F., Wang, S., Liu, B., Chen, L., Lu, Q., et al. (2025) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/jckjcq
Metadata
- Authors
- Martyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., Marangoni, R. G., Goldin, J., Whitfield, M. L., & Varga, J.
- Affiliations
- Dartmouth College (US)
- University of California, Los Angeles (US)
- Bristol-Myers Squibb (United States) (US)
- Medical University of South Carolina (US)
- Michigan Medicine (US)
- Northwestern University (US)
- Corresponding author
- Martyanov, Viktor
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-11-09
- Volume
- 12
- Issue
- 11
- Pages
- e0187580
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5679625
- OpenAlex
- W2767490418
- Semantic Scholar
- bfa1d94362f618289897f4bec86bf972703f3b4e
- Cited by
- 71
- References
- 57
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 12 · 2020: 10 · 2019: 13 · 2018: 8
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K01AR051052, P50AR060780)
- National Institutes of Health (P30AR061271)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- systemic sclerosis, systemic sclerosis-associated interstitial lung disease, dasatinib, tyrosine kinase inhibitors, lung imaging biomarkers, high-resolution computed tomography, skin fibrosis, lung function, lung fibrosis progression, modified Rodnan skin score, treatment response biomarkers
- MeSH terms
- Dasatinib, Adult, Aged, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Scleroderma, Systemic, Skin, Tomography, X-Ray Computed, Biomarkers, Lung Diseases, Interstitial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.